[1] WHO. Global tuberculosis report 2019. Geneva: WHO, 2019.
[2] Löfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis, 2010; 50 Suppl 1, S16-23.
[3] Hernández Ceruelos A, Romero-Quezada LC, Ruvalcaba Ledezma JC, et al. Therapeutic uses of metronidazole and its side effects: an update. Eur Rev Med Pharmacol Sci, 2019; 23, 397−401.
[4] Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 1994; 38, 2054−8. doi:  10.1128/AAC.38.9.2054
[5] Lin PL, Dartois V, Johnston PJ, et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci USA, 2012; 109, 14188−93. doi:  10.1073/pnas.1121497109
[6] Lu J, Wang X, Xia B, et al. Solution structure of Apo-YjaB from Escherichia coli. Proteins, 2009; 76, 261−5. doi:  10.1002/prot.22407
[7] Olekhnovich IN, Goodwin A, Hoffman PS. Characterization of the NAD(P)H oxidase and metronidazole reductase activities of the RdxA nitroreductase of Helicobacter pylori. FEBS J, 2009; 276, 3354−64. doi:  10.1111/j.1742-4658.2009.07060.x
[8] Sassetti CM, Rubin EJ. Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci USA, 2003; 100, 12989−94. doi:  10.1073/pnas.2134250100
[9] Voskuil MI, Schnappinger D, Visconti KC, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med, 2003; 198, 705−13. doi:  10.1084/jem.20030205
[10] Martinez-Júlvez M, Rojas AL, Olekhnovich I, et al. Structure of RdxA-an oxygen-insensitive nitroreductase essential for metronidazole activation in Helicobacter pylori. FEBS J, 2012; 279, 4306−17. doi:  10.1111/febs.12020